Microdose Semaglutide: A Physician's Guide to Low-Dose GLP-1 Therapy

By Brandon Phillips — May 26, 2026

What microdose semaglutide actually is, who it's for, the dosing range, expected results, and how it compares to standard 2.4 mg therapy.

"Microdosing" semaglutide means using doses below the FDA-approved 2.4 mg weight-loss target — typically in the 0.1 mg to 1.0 mg weekly range. It's become a popular approach for patients who don't need or can't tolerate the maximum dose.

Here's what we tell patients about it.

What microdose semaglutide actually is

The FDA-approved Wegovy® titration goes 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16–20 weeks. Microdosing keeps you at a lower dose long-term — most commonly 0.1 mg, 0.25 mg, or 0.5 mg weekly — instead of climbing to 2.4 mg.

It's not officially recognized in the FDA labeling, but it's a valid clinical approach used by many physicians for the right patient.

Who microdosing is right for

  • GLP-1-sensitive patients who get significant nausea or fatigue at standard doses.
  • Patients with 10–25 lb to lose rather than 50+.
  • Maintenance phase patients who reached their goal and want a sustainable long-term dose.
  • Patients who want appetite control without dramatic weight loss.
  • Aesthetics / wellness patients focused on metabolic health markers (fasting insulin, HbA1c) rather than the scale.

Who microdosing is not right for

  • Patients with significant weight loss goals (>40 lb) — you'll plateau early.
  • Patients with type 2 diabetes needing meaningful HbA1c reduction.
  • Patients who tolerated the standard dose well and want maximum effect.

Typical microdose range

Dose Use case
0.1 mg / week Ultra-low entry; metabolic / appetite-control focus
0.25 mg / week Standard entry dose; long-term tolerability
0.5 mg / week Mid-range; most common maintenance dose
1.0 mg / week Upper microdose range; effective for moderate weight loss

Realistic results

At 0.25–0.5 mg microdoses, expect:

  • 5–10% body weight loss over 6–12 months.
  • Strong appetite suppression with minimal GI side effects.
  • Improved fasting glucose and insulin sensitivity.
  • Lower likelihood of muscle loss compared to rapid weight loss at 2.4 mg.

Microdose vs standard dose — at a glance

Microdose (0.25–0.5 mg) Standard (2.4 mg)
Avg weight loss at 1 yr 5–10% 14.9%
GI side effects Mild Moderate–significant
Fatigue / lethargy Rare Common in titration
Cost Lower Higher
Best for Tolerability, maintenance, mild loss Maximum weight loss

How GOAL.MD does microdosing

Our Semaglutide Micro-Dose Program starts at $197/month with a 3-month commitment. Your physician selects your starting dose, monitors your response, and adjusts as needed. See full details on the micro-dose program page or take the 3-minute intake.

FAQs

Is microdosing as effective as 2.4 mg? Not for maximum weight loss. It's effective for appetite control, mild weight loss, and metabolic health.

Can I start at a microdose and increase later? Yes. Many patients begin microdosing and titrate up if they need more effect.

Are side effects really that much lower? In our practice, yes — patients on 0.25–0.5 mg report dramatically fewer GI symptoms than patients on 1.7–2.4 mg.

Medically Reviewed

Dr. Michael "Ted" Mimlitz, MD

Medically Reviewed by

Dr. Michael “Ted” Mimlitz, MD

Internal Medicine, Telehealth & Wellness

NPI: 1508891870
· Reviewed May 26, 2026

Reviewed on behalf of Pro Medical Reviews, LLC (NPI 1477321198).
Questions? Contact customer@jellyfish.md.

References

  1. Wilding JPH et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (STEP 1). N Engl J Med. 2021;384:989–1002. Link
  2. FDA Prescribing Information — Wegovy (semaglutide) injection. Link
  3. American Gastroenterological Association. "Pharmacological Interventions for Adults with Obesity." Gastroenterology. 2022. Link

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any treatment.

Medically reviewed by Dr. Michael Mimlitz, MD (NPI 1508891870), Chief Physician of GOAL.MD. Physician-supervised telehealth. More at goal.md/blog.